tiprankstipranks
Advertisement
Advertisement

GNLX Stock Latest News

Buy Rating Reaffirmed on Olvi-Vec Progress and Data Outlook; $31 Price Target Maintained
RatingsBuy Rating Reaffirmed on Olvi-Vec Progress and Data Outlook; $31 Price Target Maintained
3M ago
GNLX
Genelux reports Q1 EPS (20c), consensus (19c)
PremiumThe Fly
Genelux reports Q1 EPS (20c), consensus (19c)
3M ago
GNLX
Buy Rating Backed by Pivotal Olvi-Vec Ovarian Cancer Trial Progress and Multi-Indication Upside Potential
PremiumRatings
Buy Rating Backed by Pivotal Olvi-Vec Ovarian Cancer Trial Progress and Multi-Indication Upside Potential
5M ago
GNLX
Genelux price target lowered to $20 from $23 at Benchmark
PremiumThe Fly
Genelux price target lowered to $20 from $23 at Benchmark
5M ago
GNLX
Genelux: Advancing Olvi-Vec Pivotal Program and Manufacturing Readiness Underpin Buy Rating and Long-Term Value Upside
PremiumRatings
Genelux: Advancing Olvi-Vec Pivotal Program and Manufacturing Readiness Underpin Buy Rating and Long-Term Value Upside
5M ago
GNLX
Genelux Establishes $100 Million At-The-Market Equity Program
PremiumCompany AnnouncementsGenelux Establishes $100 Million At-The-Market Equity Program
5M ago
8K
GNLX
Genelux Updates Corporate Presentation for Investors and Stakeholders
Premium
Company Announcements
Genelux Updates Corporate Presentation for Investors and Stakeholders
6M ago
8K
GNLX
Genelux Announces Underwritten Public Offering to Raise Capital
Premium
Company Announcements
Genelux Announces Underwritten Public Offering to Raise Capital
7M ago
8K
GNLX
Genelux prices 6.67M shares at $3.00 in underwritten public offering
PremiumThe Fly
Genelux prices 6.67M shares at $3.00 in underwritten public offering
7M ago
GNLX
Genelux announces common stock offering, no amount given
PremiumThe Fly
Genelux announces common stock offering, no amount given
7M ago
GNLX
Genelux data update indicates disease early control, says H.C. Wainwright
PremiumThe Fly
Genelux data update indicates disease early control, says H.C. Wainwright
7M ago
GNLX
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer
PremiumRatings
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer
7M ago
GNLX
Genelux Reports Encouraging Interim Data for Olvi-Vec Trials
PremiumCompany AnnouncementsGenelux Reports Encouraging Interim Data for Olvi-Vec Trials
7M ago
8K
GNLX
Genelux reports interim data of systemic administration of Olvi-Vec
Premium
The Fly
Genelux reports interim data of systemic administration of Olvi-Vec
7M ago
GNLX
Genelux Appoints Veteran Oncologist Jason Litten as CMO
Premium
Company Announcements
Genelux Appoints Veteran Oncologist Jason Litten as CMO
7M ago
8K
GNLX
Genelux appoints Jason Litten as CMO
PremiumThe Fly
Genelux appoints Jason Litten as CMO
7M ago
GNLX
Genelux Corp’s Promising Oncolytic Virus Advancements and Market Potential Drive Buy Rating
PremiumRatings
Genelux Corp’s Promising Oncolytic Virus Advancements and Market Potential Drive Buy Rating
9M ago
GNLX
Promising Clinical Developments in Genelux Corp.’s Olvi-Vec Trials Support Buy Rating
PremiumRatings
Promising Clinical Developments in Genelux Corp.’s Olvi-Vec Trials Support Buy Rating
9M ago
GNLX
Genelux reports Q3 EPS (21c), consensus (21c)
PremiumThe Fly
Genelux reports Q3 EPS (21c), consensus (21c)
9M ago
GNLX
Genelux initiated with a Buy at Titan Partners
PremiumThe FlyGenelux initiated with a Buy at Titan Partners
9M ago
GNLX
Genelux Corp.’s OnPrime Study: A Potential Game-Changer in Ovarian Cancer Treatment
Premium
Company Announcements
Genelux Corp.’s OnPrime Study: A Potential Game-Changer in Ovarian Cancer Treatment
9M ago
GNLX
Genelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment
Premium
Company Announcements
Genelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment
9M ago
GNLX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >